X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8666) 8666
Newsletter (31) 31
Magazine Article (23) 23
Newspaper Article (16) 16
Book Chapter (6) 6
Book / eBook (5) 5
Conference Proceeding (2) 2
Dissertation (1) 1
Government Document (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7205) 7205
male (4348) 4348
pyridines - adverse effects (3969) 3969
female (3787) 3787
pyridines - therapeutic use (3530) 3530
middle aged (2913) 2913
adult (2464) 2464
pyridines - administration & dosage (2267) 2267
aged (2210) 2210
animals (1968) 1968
pyridines - pharmacology (1920) 1920
pharmacology & pharmacy (1617) 1617
treatment outcome (1305) 1305
oncology (1275) 1275
dose-response relationship, drug (914) 914
pyridines - pharmacokinetics (886) 886
niacinamide - analogs & derivatives (832) 832
antineoplastic agents - therapeutic use (801) 801
phenylurea compounds (797) 797
cancer (770) 770
double-blind method (742) 742
rats (736) 736
antineoplastic agents - adverse effects (733) 733
care and treatment (691) 691
administration, oral (672) 672
drug therapy (666) 666
aged, 80 and over (629) 629
analysis (627) 627
mice (620) 620
research (589) 589
time factors (544) 544
safety (525) 525
clinical trials as topic (513) 513
medicine & public health (506) 506
drug administration schedule (502) 502
pharmacokinetics (502) 502
drug therapy, combination (501) 501
protein kinase inhibitors - therapeutic use (491) 491
benzenesulfonates - adverse effects (482) 482
sorafenib (479) 479
risk factors (475) 475
drug interactions (459) 459
benzenesulfonates - therapeutic use (456) 456
therapy (450) 450
abridged index medicus (445) 445
adolescent (444) 444
young adult (441) 441
protein kinase inhibitors - adverse effects (440) 440
hiv infections - drug therapy (432) 432
atazanavir sulfate (429) 429
clinical trials (427) 427
chemotherapy (426) 426
medicine, general & internal (424) 424
efficacy (423) 423
double-blind (421) 421
neurosciences (412) 412
antineoplastic combined chemotherapy protocols - therapeutic use (390) 390
health aspects (389) 389
hypnotics and sedatives - adverse effects (377) 377
pharmacology/toxicology (373) 373
cardiac & cardiovascular systems (364) 364
dabigatran (357) 357
toxicology (356) 356
drug combinations (355) 355
pyridines (352) 352
zolpidem (351) 351
pyridine (349) 349
disease models, animal (339) 339
pharmacology (332) 332
dosage and administration (328) 328
anticoagulants - adverse effects (319) 319
internal medicine (317) 317
randomized controlled trials as topic (314) 314
prevention (311) 311
expression (309) 309
retrospective studies (299) 299
pyridines - chemistry (296) 296
patients (295) 295
carcinoma, renal cell - drug therapy (292) 292
infectious diseases (291) 291
antineoplastic agents - administration & dosage (290) 290
metastasis (289) 289
pyrazoles - therapeutic use (289) 289
psychiatry (287) 287
kidney neoplasms - drug therapy (286) 286
oligopeptides - adverse effects (286) 286
toxicity (285) 285
rats, sprague-dawley (278) 278
liver neoplasms - drug therapy (276) 276
lung neoplasms - drug therapy (276) 276
risk (273) 273
clinical neurology (272) 272
antineoplastic combined chemotherapy protocols - adverse effects (270) 270
hemorrhage - chemically induced (269) 269
hematology (267) 267
disease-free survival (265) 265
follow-up studies (263) 263
anticoagulants - therapeutic use (261) 261
imidazoles - pharmacology (259) 259
pyrazoles - adverse effects (255) 255
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8170) 8170
Japanese (181) 181
German (173) 173
French (125) 125
Spanish (74) 74
Italian (26) 26
Russian (26) 26
Chinese (24) 24
Swedish (14) 14
Danish (8) 8
Dutch (7) 7
Hungarian (6) 6
Norwegian (5) 5
Polish (5) 5
Czech (4) 4
Croatian (2) 2
Finnish (1) 1
Hebrew (1) 1
Portuguese (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
.... This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails... 
Dermatology | CELL LUNG-CANCER | CHRONIC MYELOGENOUS LEUKEMIA | GROWTH-FACTOR RECEPTOR | PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | RADIATION-RECALL DERMATITIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE-KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | HAND-FOOT SYNDROME | DERMATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Drug Eruptions - pathology | Humans | Antibodies, Monoclonal - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Fusion Proteins, bcr-abl | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug-Related Side Effects and Adverse Reactions | Hair Diseases - chemically induced | Pyrroles - adverse effects | Mucous Membrane - drug effects | Cetuximab | Taxoids - adverse effects | Platinum Compounds - adverse effects | Drug Eruptions - etiology | Skin Diseases - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Antimetabolites - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Pyrimidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Proteasome Inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Chemotherapy | Platelet-derived growth factor | Formulae, receipts, prescriptions | Dermatologic agents | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
The Journal of infectious diseases, ISSN 1537-6613, 2011, Volume 203, Issue 12, pp. 1791 - 1801
Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV... 
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | INFECTIOUS DISEASES | EFFICACY | INITIATION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | COMBINATION | OSTEOPOROSIS | HIV-INFECTED PATIENTS | WOMEN | THERAPY | COHORT | HEALTH | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Major and Brief Reports
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
.... In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Neuropharmacology, ISSN 0028-3908, 2013, Volume 71, pp. 83 - 97
Serotonin (5-HT) is a neurotransmitter that is involved in many behavioral functions, including the organization of defense, and its putative pathological... 
Fear | Zebrafish | Anxiety | Serotonin | Scototaxis | Geotaxis | 5-HYDROXYTRYPTAMINE RELEASE | RAT | MOUSE | REUPTAKE INHIBITORS | DORSAL RAPHE | PLUS-MAZE BEHAVIOR | NEUROSCIENCES | RECEPTOR ANTAGONIST | HIPPOCAMPUS | 5-HT1A | PHARMACOLOGY & PHARMACY | MICE | Anti-Anxiety Agents - administration & dosage | Fenclonine - administration & dosage | Spiro Compounds - therapeutic use | Anxiety - drug therapy | Piperidones - therapeutic use | Serotonin - chemistry | Brain - metabolism | Pyridines - adverse effects | Fenclonine - adverse effects | Behavior, Animal - drug effects | Hyperkinesis - chemically induced | Neurons - metabolism | Serotonin 5-HT1 Receptor Antagonists - administration & dosage | Anti-Anxiety Agents - therapeutic use | Buspirone - therapeutic use | Fluoxetine - adverse effects | Disease Models, Animal | Pyridines - administration & dosage | Nerve Tissue Proteins - agonists | Piperazines - therapeutic use | Piperazines - adverse effects | Extracellular Fluid - drug effects | Brain - drug effects | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Piperazines - administration & dosage | Fenclonine - therapeutic use | Spiro Compounds - administration & dosage | Piperidones - adverse effects | Hyperkinesis - metabolism | Spiro Compounds - adverse effects | Dose-Response Relationship, Drug | Buspirone - administration & dosage | Protein Isoforms - metabolism | Protein Isoforms - agonists | Anti-Anxiety Agents - adverse effects | Buspirone - adverse effects | Fluoxetine - therapeutic use | Neurons - drug effects | Anxiety - metabolism | Pyridines - therapeutic use | Nerve Tissue Proteins - antagonists & inhibitors | Serotonin Uptake Inhibitors - therapeutic use | Serotonin Uptake Inhibitors - adverse effects | Serotonin 5-HT1 Receptor Agonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - adverse effects | Serotonin 5-HT1 Receptor Antagonists - adverse effects | Nerve Tissue Proteins - metabolism | Piperidones - administration & dosage | Extracellular Fluid - metabolism | Serotonin 5-HT1 Receptor Antagonists - therapeutic use | Animals | Serotonin - metabolism | Serotonin 5-HT1 Receptor Agonists - administration & dosage | Anxiety - chemically induced | Protein Isoforms - antagonists & inhibitors | Phenols | Buspirone hydrochloride | Fluoxetine
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
.... Risk ratios (RR) for VTE and bleed end-points were estimated using fixed and random effects meta-analysis... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | ENOXAPARIN | meta-analysis | RANDOMIZED-TRIAL | REPLACEMENT | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | THROMBOSIS PROPHYLAXIS | US HOSPITALS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | REGISTRY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4782, 2009, Volume 6, Issue 8, pp. 465 - 477
.... with expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions... 
ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | TYROSINE KINASE INHIBITOR | PHASE-II | OVARIAN-CANCER | PACLITAXEL PLUS BEVACIZUMAB | THROMBOTIC MICROANGIOPATHY | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | COOPERATIVE-ONCOLOGY-GROUP | Humans | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Benzenesulfonates - adverse effects | Bevacizumab | Brain Diseases - chemically induced | Benzenesulfonates - pharmacology | Pyridines - adverse effects | Drug Interactions | Kidney Diseases - chemically induced | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal - pharmacology | Risk Factors | Angiogenesis Inhibitors - pharmacology | Forecasting | Indoles - adverse effects | Indoles - therapeutic use | Cardiovascular Diseases - chemically induced | Hemorrhage - chemically induced | Vascular Endothelial Growth Factor A - physiology | Niacinamide - analogs & derivatives | Receptors, Vascular Endothelial Growth Factor - physiology | Clinical Trials as Topic - statistics & numerical data | Neoplasm Proteins - physiology | Antibodies, Monoclonal - adverse effects | Cardiovascular Diseases - therapy | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Drug Delivery Systems | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Pyrroles - therapeutic use | Wound Healing - drug effects | Pyridines - therapeutic use | Hemorrhage - therapy | Pyrroles - pharmacology | Protein Kinase Inhibitors - therapeutic use | Capillary Leak Syndrome - chemically induced | Kidney Diseases - therapy | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Gastrointestinal Diseases - chemically induced | Antimitotic agents | Complications and side effects | Care and treatment | Colorectal cancer | Physiological aspects | Development and progression | Poisoning | Antineoplastic agents | Vascular endothelial growth factor | Risk factors | Tumors | Cancer | Index Medicus
Journal Article